Milestone Scientific (MLSS) investor relations material

Company overview and business model

• Patents, designs, develops, and commercializes computer-controlled injection technologies for medical and dental use, focusing on precise, efficient, and virtually painless drug delivery.

• Core technology is the DPS Dynamic Pressure Sensing platform, enabling real-time pressure feedback and advanced injection control.

• Products include the CompuDent and STA Single Tooth Anesthesia System for dental use, and the CompuFlo Epidural System for medical applications, with FDA clearance and CE mark approval.

• Holds approximately 305 issued patents and 15 pending applications covering a range of drug delivery and sensing technologies.

• Recent CPT code approval for the CompuFlo Epidural System is expected to accelerate adoption in pain management clinics.

Financial performance and metrics

• Identified as a smaller reporting company with a history of limited revenue and significant operating losses, which are expected to continue.

• Financial statements for 2025 audited by CBIZ CPAs, with a going concern uncertainty noted; prior years audited by Marcum LLP.

• As of September 8, 2026, 90,644,403 shares of common stock were issued and outstanding.

Use of proceeds and capital allocation

• Net proceeds will be used for working capital, general corporate purposes, research and development, general and administrative expenses, capital expenditures, and potentially for licensing or acquiring intellectual property or technologies.

• Management has broad discretion over allocation of proceeds; no current plans for acquisitions.